Functionally Distinct Subpopulations of Cpg-Activated Memory B Cells SUBJECT AREAS: Alicia D
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only. -
Of Keeping and Tipping the Balance: Host Regulation and Viral Modulation of IRF3-Dependent IFNB1 Expression
viruses Review Of Keeping and Tipping the Balance: Host Regulation and Viral Modulation of IRF3-Dependent IFNB1 Expression Hella Schwanke 1,2 , Markus Stempel 1,2 and Melanie M. Brinkmann 1,2,* 1 Institute of Genetics, Technische Universität Braunschweig, 38106 Braunschweig, Germany; [email protected] (H.S.); [email protected] (M.S.) 2 Viral Immune Modulation Research Group, Helmholtz Centre for Infection Research, 38124 Braunschweig, Germany * Correspondence: [email protected]; Tel.: +49-531-6181-3069 Received: 15 June 2020; Accepted: 3 July 2020; Published: 7 July 2020 Abstract: The type I interferon (IFN) response is a principal component of our immune system that allows to counter a viral attack immediately upon viral entry into host cells. Upon engagement of aberrantly localised nucleic acids, germline-encoded pattern recognition receptors convey their find via a signalling cascade to prompt kinase-mediated activation of a specific set of five transcription factors. Within the nucleus, the coordinated interaction of these dimeric transcription factors with coactivators and the basal RNA transcription machinery is required to access the gene encoding the type I IFN IFNβ (IFNB1). Virus-induced release of IFNβ then induces the antiviral state of the system and mediates further mechanisms for defence. Due to its key role during the induction of the initial IFN response, the activity of the transcription factor interferon regulatory factor 3 (IRF3) is tightly regulated by the host and fiercely targeted by viral proteins at all conceivable levels. In this review, we will revisit the steps enabling the trans-activating potential of IRF3 after its activation and the subsequent assembly of the multi-protein complex at the IFNβ enhancer that controls gene expression. -
CD226 T Cells Expressing the Receptors TIGIT and Divergent Phenotypes of Human Regulatory
The Journal of Immunology Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226 Christopher A. Fuhrman,*,1 Wen-I Yeh,*,1 Howard R. Seay,* Priya Saikumar Lakshmi,* Gaurav Chopra,† Lin Zhang,* Daniel J. Perry,* Stephanie A. McClymont,† Mahesh Yadav,† Maria-Cecilia Lopez,‡ Henry V. Baker,‡ Ying Zhang,x Yizheng Li,{ Maryann Whitley,{ David von Schack,x Mark A. Atkinson,* Jeffrey A. Bluestone,‡ and Todd M. Brusko* Regulatory T cells (Tregs) play a central role in counteracting inflammation and autoimmunity. A more complete understanding of cellular heterogeneity and the potential for lineage plasticity in human Treg subsets may identify markers of disease pathogenesis and facilitate the development of optimized cellular therapeutics. To better elucidate human Treg subsets, we conducted direct transcriptional profiling of CD4+FOXP3+Helios+ thymic-derived Tregs and CD4+FOXP3+Helios2 T cells, followed by comparison with CD4+FOXP32Helios2 T conventional cells. These analyses revealed that the coinhibitory receptor T cell Ig and ITIM domain (TIGIT) was highly expressed on thymic-derived Tregs. TIGIT and the costimulatory factor CD226 bind the common ligand CD155. Thus, we analyzed the cellular distribution and suppressive activity of isolated subsets of CD4+CD25+CD127lo/2 T cells expressing CD226 and/or TIGIT. We observed TIGIT is highly expressed and upregulated on Tregs after activation and in vitro expansion, and is associated with lineage stability and suppressive capacity. Conversely, the CD226+TIGIT2 population was associated with reduced Treg purity and suppressive capacity after expansion, along with a marked increase in IL-10 and effector cytokine production. These studies provide additional markers to delineate functionally distinct Treg subsets that may help direct cellular therapies and provide important phenotypic markers for assessing the role of Tregs in health and disease. -
Single-Cell RNA Sequencing Demonstrates the Molecular and Cellular Reprogramming of Metastatic Lung Adenocarcinoma
ARTICLE https://doi.org/10.1038/s41467-020-16164-1 OPEN Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma Nayoung Kim 1,2,3,13, Hong Kwan Kim4,13, Kyungjong Lee 5,13, Yourae Hong 1,6, Jong Ho Cho4, Jung Won Choi7, Jung-Il Lee7, Yeon-Lim Suh8,BoMiKu9, Hye Hyeon Eum 1,2,3, Soyean Choi 1, Yoon-La Choi6,10,11, Je-Gun Joung1, Woong-Yang Park 1,2,6, Hyun Ae Jung12, Jong-Mu Sun12, Se-Hoon Lee12, ✉ ✉ Jin Seok Ahn12, Keunchil Park12, Myung-Ju Ahn 12 & Hae-Ock Lee 1,2,3,6 1234567890():,; Advanced metastatic cancer poses utmost clinical challenges and may present molecular and cellular features distinct from an early-stage cancer. Herein, we present single-cell tran- scriptome profiling of metastatic lung adenocarcinoma, the most prevalent histological lung cancer type diagnosed at stage IV in over 40% of all cases. From 208,506 cells populating the normal tissues or early to metastatic stage cancer in 44 patients, we identify a cancer cell subtype deviating from the normal differentiation trajectory and dominating the metastatic stage. In all stages, the stromal and immune cell dynamics reveal ontological and functional changes that create a pro-tumoral and immunosuppressive microenvironment. Normal resident myeloid cell populations are gradually replaced with monocyte-derived macrophages and dendritic cells, along with T-cell exhaustion. This extensive single-cell analysis enhances our understanding of molecular and cellular dynamics in metastatic lung cancer and reveals potential diagnostic and therapeutic targets in cancer-microenvironment interactions. 1 Samsung Genome Institute, Samsung Medical Center, Seoul 06351, Korea. -
CD45) 6 7 8 9 10 11 12 13 Melissa L
bioRxiv preprint doi: https://doi.org/10.1101/2020.09.29.318709; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 2 3 4 5 The roseoloviruses downregulate the protein tyrosine phosphatase PTPRC (CD45) 6 7 8 9 10 11 12 13 Melissa L. Whyte1, Kelsey Smith1, Amanda Buchberger2,4, Linda Berg Luecke 4, Lidya 14 Handayani Tjan3, Yasuko Mori3, Rebekah L Gundry2,4, and Amy W. Hudson1# 15 16 17 18 19 20 21 22 23 24 25 26 27 1: Department of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, WI 28 2. Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI 29 3. Division of Clinical Virology, Kobe University Graduate School of Medicine, Kobe, Japan 30 4: Current address: CardiOmics Program, Center for Heart and Vascular Research; Division of 31 Cardiovascular Medicine; and Department of Cellular and Integrative Physiology, University of 32 Nebraska Medical Center, Omaha, NE 33 34 35 36 #To whom correspondence should be addressed: [email protected] 37 38 39 40 Runnning title: Roseolovirus downregulation of CD45 41 42 43 44 45 46 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.09.29.318709; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 47 Abstract 48 Like all herpesviruses, the roseoloviruses (HHV6A, -6B, and -7) establish lifelong 49 infection within their host, requiring these viruses to evade host anti-viral responses. -
Binding Mode of the Side-By-Side Two-Igv Molecule CD226/DNAM-1 to Its Ligand CD155/Necl-5
Binding mode of the side-by-side two-IgV molecule CD226/DNAM-1 to its ligand CD155/Necl-5 Han Wanga, Jianxun Qib, Shuijun Zhangb,1, Yan Lib, Shuguang Tanb,2, and George F. Gaoa,b,2 aResearch Network of Immunity and Health (RNIH), Beijing Institutes of Life Science, Chinese Academy of Sciences (CAS), 100101 Beijing, China; and bCAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, 100101 Beijing, China Edited by K. Christopher Garcia, Stanford University School of Medicine, Stanford, CA, and approved December 3, 2018 (received for review September 11, 2018) Natural killer (NK) cells are important component of innate immu- CD226, also known as DNAM-1, belongs to the Ig superfamily nity and also contribute to activating and reshaping the adaptive and contains two extracellular Ig-like domains (CD226-D1 and immune responses. The functions of NK cells are modulated by CD226-D2), and is widely expressed in monocytes, platelets, multiple inhibitory and stimulatory receptors. Among these recep- T cells, and most of the resting NK cells (8, 13, 19, 20). The tors, the activating receptor CD226 (DNAM-1) mediates NK cell intracellular domain of CD226 does not contain a tyrosine-based activation via binding to its nectin-like (Necl) family ligand, CD155 activation motif, which is accepted as responsible for activating (Necl-5). Here, we present a unique side-by-side arrangement signal transduction of stimulatory molecules (13). Instead, it pattern of two tandem immunoglobulin V-set (IgV) domains transmits the downstream signaling by phosphorylation of in- deriving from the ectodomains of both human CD226 (hCD226- tracellular phosphorylation sites and subsequent association with ecto) and mouse CD226 (mCD226-ecto), which is substantially integrin lymphocyte function-associated antigen 1 (21). -
Cytokine Regulation in Human CD4 T Cells by the Aryl Hydrocarbon
www.nature.com/scientificreports OPEN Cytokine Regulation in Human CD4 T Cells by the Aryl Hydrocarbon Receptor and Gq-Coupled Received: 17 November 2017 Accepted: 9 July 2018 Receptors Published: xx xx xxxx Jeremy P. McAleer1, Jun Fan2, Bryanna Roar1, Donald A. Primerano2 & James Denvir2 Th17 cells contribute to host defense on mucosal surfaces but also provoke autoimmune diseases when directed against self-antigens. Identifying therapeutic targets that regulate Th17 cell diferentiation and/or cytokine production has considerable value. Here, we study the aryl hydrocarbon receptor (AhR)- dependent transcriptome in human CD4 T cells treated with Th17-inducing cytokines. We show that the AhR reciprocally regulates IL-17 and IL-22 production in human CD4 T cells. Global gene expression analysis revealed that AhR ligation decreased IL21 expression, correlating with delayed upregulation of RORC during culture with Th17-inducing cytokines. Several of the AhR-dependent genes have known roles in cellular assembly, organization, development, growth and proliferation. We further show that expression of GPR15, GPR55 and GPR68 positively correlates with IL-22 production in the presence of the AhR agonist FICZ. Activation of GPR68 with the lorazepam derivative ogerin resulted in suppression of IL-22 and IL-10 secretion by T cells, with no efect on IL-17. Under neutral Th0 conditions, ogerin and the Gq/11 receptor inhibitor YM254890 blunted IL-22 induction by FICZ. These data reveal the AhR- dependent transcriptome in human CD4 T cells and suggest the mechanism through which the AhR regulates T cell function may be partially dependent on Gq-coupled receptors including GPR68. -
Type I Interferons in Anticancer Immunity
REVIEWS Type I interferons in anticancer immunity Laurence Zitvogel1–4*, Lorenzo Galluzzi1,5–8*, Oliver Kepp5–9, Mark J. Smyth10,11 and Guido Kroemer5–9,12 Abstract | Type I interferons (IFNs) are known for their key role in antiviral immune responses. In this Review, we discuss accumulating evidence indicating that type I IFNs produced by malignant cells or tumour-infiltrating dendritic cells also control the autocrine or paracrine circuits that underlie cancer immunosurveillance. Many conventional chemotherapeutics, targeted anticancer agents, immunological adjuvants and oncolytic 1Gustave Roussy Cancer Campus, F-94800 Villejuif, viruses are only fully efficient in the presence of intact type I IFN signalling. Moreover, the France. intratumoural expression levels of type I IFNs or of IFN-stimulated genes correlate with 2INSERM, U1015, F-94800 Villejuif, France. favourable disease outcome in several cohorts of patients with cancer. Finally, new 3Université Paris Sud/Paris XI, anticancer immunotherapies are being developed that are based on recombinant type I IFNs, Faculté de Médecine, F-94270 Le Kremlin Bicêtre, France. type I IFN-encoding vectors and type I IFN-expressing cells. 4Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, F-94800 Villejuif, France. Type I interferons (IFNs) were first discovered more than Type I IFNs in cancer immunosurveillance 5Equipe 11 labellisée par la half a century ago as the factors underlying viral inter Type I IFNs are known to mediate antineoplastic effects Ligue Nationale contre le ference — that is, the ability of a primary viral infection against several malignancies, which is a clinically rel Cancer, Centre de Recherche 1 des Cordeliers, F-75006 Paris, to render cells resistant to a second distinct virus . -
Strong ALK and PD-L1 Positive IHC Expression Related ALK Amplification in an Advanced Lung Sarcomatoid Carcinoma
Strong ALK and PD-L1 positive IHC expression related ALK amplification in an advanced lung sarcomatoid carcinoma: a therapeutic trap? Sébastien Gendarme, Lise Matton, Martine Antoine, Khaldoun Kerrou, Anne-Marie Ruppert, Christelle Epaud, Jacques Cadranel, Vincent Fallet To cite this version: Sébastien Gendarme, Lise Matton, Martine Antoine, Khaldoun Kerrou, Anne-Marie Ruppert, et al.. Strong ALK and PD-L1 positive IHC expression related ALK amplification in an advanced lung sarcomatoid carcinoma: a therapeutic trap?. Lung Cancer, Elsevier, 2020, 152, pp.94-97. 10.1016/j.lungcan.2020.12.022. hal-03263433 HAL Id: hal-03263433 https://hal.sorbonne-universite.fr/hal-03263433 Submitted on 17 Jun 2021 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Strong ALK and PD-L1 positive IHC expression related ALK amplification in an advanced lung sarcomatoid carcinoma: a therapeutic trap? Sébastien Gendarmea ; Lise Mattona ; Martine Antoineb ; Khaldoun Kerrouc ; Anne-Marie Ruppert a; Christelle Epaud a ; Jacques Cadranel a ; Vincent Fallet a Affiliations : a Department of Pneumology and Thoracic Oncology, Tenon Hospital, Assistance Publique- Hôpitaux de Paris and GRC 4, Theranoscan, Sorbonne Université, 75970 Paris, France. b Pathology Department, AP-HP, Groupe Hospitalier HUEP, Hôpital Tenon, Paris, France. -
CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity a C Suresh De Silva, George Fromm, Casey W
Published OnlineFirst December 18, 2019; DOI: 10.1158/2326-6066.CIR-19-0493 CANCER IMMUNOLOGY RESEARCH | RESEARCH ARTICLE CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity A C Suresh de Silva, George Fromm, Casey W. Shuptrine, Kellsey Johannes, Arpita Patel, Kyung Jin Yoo, Kaiwen Huang, and Taylor H. Schreiber ABSTRACT ◥ Disrupting the binding of CD47 to SIRPa has emerged as a No evidence of hemolysis, hemagglutination, or thrombocytopenia promising immunotherapeutic strategy for advanced cancers by was observed in vitro or in cynomolgus macaques. Murine SIRPa- potentiating antibody-dependent cellular phagocytosis (ADCP) of Fc-CD40L outperformed CD47 blocking and CD40 agonist anti- targeted antibodies. Preclinically, CD47/SIRPa blockade induces bodies in murine CT26 tumor models and synergized with immune antitumor activity by increasing the phagocytosis of tumor cells by checkpoint blockade of PD-1 and CTLA4. SIRPa-Fc-CD40L acti- macrophages and enhancing the cross-presentation of tumor anti- vated a type I interferon response in macrophages and potentiated þ gens to CD8 T cells by dendritic cells; both of these processes are the activity of ADCP-competent targeted antibodies both in vitro and potentiated by CD40 signaling. Here we generated a novel, two-sided in vivo. These data illustrated that whereas CD47/SIRPa inhibition fusion protein incorporating the extracellular domains of SIRPa and could potentiate tumor cell phagocytosis, CD40-mediated activation CD40L, adjoined by a central Fc domain, termed SIRPa-Fc-CD40L. of a type I interferon response provided a bridge between macro- SIRPa-Fc-CD40L bound CD47 and CD40 with high affinity and phage- and T-cell–mediated immunity that significantly enhanced activated CD40 signaling in the absence of Fc receptor cross-linking. -
Supplemental Figures and Figure Legends
Supplemental Figures and Figure Legends A Source Hirst REMC 1 Source Hirst REMC Source Hirst Source 1 0.9 0.8 0.7 0.6 0.9 REMC 1 0.9 0.8 0.7 0.6 Source Source B Penis_Foreskin_Melanocyte_Primary_Cells_skin03 Penis_Foreskin_Melanocyte_Primary_Cells_skin01 Penis_Foreskin_Melanocyte_Primary_Cells_skin03 0.8HUVEC Penis_Foreskin_Melanocyte_Primary_Cells_skin01 Penis_Foreskin_Fibroblast_Primary_Cells_skin02 Penis_Foreskin_Fibroblast_Primary_Cells_skin01 HUVEC H1_Derived_Mesenchymal_Stem_Cells Penis_Foreskin_Fibroblast_Primary_Cells_skin02 NHLF 0.7HSMM Penis_Foreskin_Fibroblast_Primary_Cells_skin01 Universal_Human_Reference H1_Derived_Mesenchymal_Stem_Cells NHEK Breast_vHMEC NHLF HMEC HSMM Penis_Foreskin_Keratinocyte_Primary_Cells_skin03 0.6Penis_Foreskin_Keratinocyte_Primary_Cells_skin02 Universal_Human_Reference Breast_Myoepithelial_Cells NHEK HELA A549 Breast_vHMEC HEPG2 HMEC hESC_Derived_CD56+_Mesoderm_Cultured_Cells H1_BMP4_Derived_Trophoblast_Cultured_Cells Penis_Foreskin_Keratinocyte_Primary_Cells_skin03 HUES64_Cell_Line Penis_Foreskin_Keratinocyte_Primary_Cells_skin02 H1_BMP4_Derived_Mesendoderm_Cultured_Cells Breast_Myoepithelial_Cells 4star H1_Cell_Line HELA hESC_Derived_CD56+_Ectoderm_Cultured_Cells A549 H1_Derived_Neuronal_Progenitor_Cultured_Cells hESC_Derived_CD184+_Endoderm_Cultured_Cells HEPG2 Neurosphere_Cultured_Cells_Ganglionic_Eminence_Derived hESC_Derived_CD56+_Mesoderm_Cultured_Cells Neurosphere_Cultured_Cells_Cortex_Derived Brain_Germinal_Matrix H1_BMP4_Derived_Trophoblast_Cultured_Cells Fetal_Brain_Female HUES64_Cell_Line -
Jp 6257125 B2 2018.1.10 (57)【特許請求の範囲】 【請求項1】 以下の工程を含み、対象から得られた
JP 6257125 B2 2018.1.10 (57)【特許請求の範囲】 【請求項1】 以下の工程を含み、対象から得られた甲状腺組織の試料を甲状腺状態について良性また は悪性として分類する方法: (a)前記甲状腺組織の試料の第1の部分に対して、該甲状腺組織の試料を不明確または 疑わしいものとして同定する細胞学的試験を行う工程; (b)発現分析のために少なくとも50の遺伝子を選択する工程であって、該少なくとも 50の遺伝子は、リスト1: (2) JP 6257125 B2 2018.1.10 10 20 30 40 (3) JP 6257125 B2 2018.1.10 10 20 30 40 (4) JP 6257125 B2 2018.1.10 10 20 からの遺伝子を含む、工程; (c)前記細胞学的試験により甲状腺組織の試料を不明確または疑わしいものとして同定 30 する工程に基づいて、少なくとも50の遺伝子発現産物の発現のレベルについて該甲状腺 組織の試料の第2の部分をアッセイする工程であって、該少なくとも50の遺伝子発現産 物は、前記少なくとも50の遺伝子に対応する、工程;および (d)前記少なくとも50の遺伝子発現産物の発現レベルを前記甲状腺状態と相関させる ことによって、甲状腺組織の該試料を前記甲状腺状態について良性または悪性として分類 する工程。 【請求項2】 工程(d)における相関が、訓練されたアルゴリズムを用いて行われ、ここで、該訓練 されたアルゴリズムは、訓練試料を含む訓練セットで訓練されている、請求項1記載の方 法。 40 【請求項3】 該訓練されたアルゴリズムが、工程(c)の少なくとも50の遺伝子発現産物の発現のレ ベルを甲状腺組織の少なくとも3個の訓練試料からの発現データと相関させ、甲状腺組織 の該少なくとも3個の訓練組織のそれぞれが異なる組織型より得られ、かつ該異なる組織 型が、濾胞性腺腫、濾胞癌、リンパ性甲状腺炎、濾胞型甲状腺乳頭癌(follicular varia nt papillary thyroid carcinoma)、甲状腺乳頭癌、結節性過形成、甲状腺髄様癌、ハー スル細胞癌、ハースル細胞腺腫、甲状腺未分化癌、転移性黒色腫、転移性腎癌、転移性乳 癌、副甲状腺、および転移性B細胞リンパ腫の組織型より選択される、請求項2記載の方 法。 【請求項4】 50 (5) JP 6257125 B2 2018.1.10 前記訓練されたアルゴリズムが、工程(c)の少なくとも50の遺伝子発現産物の発現の レベルを複数の試料から得られた発現データと相関させ、該複数の試料が、非甲状腺器官 からの転移性癌である病態を有する試料を含む、請求項2記載の方法。 【請求項5】 前記少なくとも50の遺伝子発現産物がRNA発現産物である、請求項1記載の方法。 【請求項6】 前記RNA発現産物のレベルが、マイクロアレイ、SAGE、ブロッティング、RT-PCR、定量 的PCR、または配列決定により測定される、請求項5記載の方法。 【請求項7】 前記訓練されたアルゴリズムが、少なくとも3個の訓練試料により訓練され、該少なく 10 とも3個の訓練試料のそれぞれが異なる悪性病態を示す、請求項2記載の方法。 【請求項8】 前記訓練セットが、転移性黒色腫、転移性腎癌、転移性乳癌、および転移性B細胞リン パ腫からなる群より選択される病態を有する訓練試料を含む、請求項2記載の方法。 【請求項9】 前記訓練セットが、 (i)細針吸引によって得られた訓練試料;または (ii)細針吸引によって得られた訓練試料および外科的生検により得られた訓練試料 を含む、請求項2記載の方法。